BRCA1 Promoter Methylation in Ovarian Cancer: Clinical Relevance and a Novel Diagnostic Approach Using Fragment Analysis
Cancer Science · 2025
DOI: 10.1111/cas.70078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Saki Tsuchimochi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: DNA Methylation, Promoter Regions, Genetic, Ovarian Neoplasms, BRCA1 Protein. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Homologous recombination deficiency (HRD) tests, including MyChoice CDx, are companion diagnostics for poly (ADP‐ribose) polymerase (PARP) inhibitors. BRCA1 promoter hypermethylation, a major HRD cause, may correlate with poorer prognosis. This study aimed to develop a simple, accurate method for detecting BRCA1 promoter hypermethylation and elucidate the characteristics of such cases. BRCA1 promoter methylation was analyzed using bisulfite sequencing (BIS‐seq) in high‐grade serous ovarian carcinoma specimens. We developed a newly developed BRCA1 methylation assay, BRCA1 ‐Fragment Analysis of Methylation ( BRCA1 ‐FAM), which combines restriction enzyme digestion with fragment analysis. The accuracy of this assay was compared to the results of BIS‐seq. We evaluated the relationship between BRCA1 promoter hypermethylation and prognosis and examined its association with BRCA1 expression and loss of heterozygosity. BRCA1 mutations and promoter methylation were mutually exclusive in the analyzed cases, with methylation observed in 28.9% (22/76) of primary debulking surgery cases. The BRCA1 ‐FAM showed high sensitivity (91.3%) and specificity (100%) for detecting BRCA1 promoter hypermethylation, comparable to BIS‐seq. Cases with BRCA1 promoter hypermethylation had significantly poorer progression‐free survival (log‐rank test, p = 0.048). Among these cases, 86.4% displayed abnormal BRCA1 immunostaining, with lower frequencies of BRCA1 loss of heterozygosity compared to those of other groups. BRCA1 promoter hypermethylation is associated with poor prognosis, underscoring the importance of its identification for HRD stratification. BRCA1 ‐FAM is a simple and highly accurate method for evaluating BRCA1 promoter methylation. This approach may potentially enhance the precision of personalized therapies for ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
- Division of Cell Therapy, Chiba Cancer Center, Research Institute, Chiba, Japan.
- Department of Pathology, The University of Tokyo, Tokyo, Japan.
- Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
- Department of Clinical Genomics, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Ayumi Taguchi, Kosei Hasegawa
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Tsuchimochi, S., Yamamoto, Y., Taguchi, A., Kawazu, M., Sone, K., Ikemura, M., Tamai, K., Kitamura, S., Yoshimoto, D., Fukaya, S., Ishizaka, A., Quynh, A. D., Nishijima, A., Miyamoto, Y., Mori, M., Hiraike, O., Hasegawa, K., Ushiku, T., Oda, K., …, & Osuga, Y. (2025). BRCA1 Promoter Methylation in Ovarian Cancer: Clinical Relevance and a Novel Diagnostic Approach Using Fragment Analysis. Cancer Science. https://doi.org/10.1111/cas.70078
Vancouver
Tsuchimochi S, Yamamoto Y, Taguchi A, Kawazu M, Sone K, Ikemura M, et al. BRCA1 Promoter Methylation in Ovarian Cancer: Clinical Relevance and a Novel Diagnostic Approach Using Fragment Analysis. Cancer Science. 2025. doi:10.1111/cas.70078
BibTeX
@article{Tsuchimochi2025,
author = {Tsuchimochi, Saki and Yamamoto, Yoko and Taguchi, Ayumi and Kawazu, Masahito and Sone, Kenbun and Ikemura, Masako and Tamai, Kana and Kitamura, Shuhei and Yoshimoto, Daisuke and Fukaya, Sayuri and Ishizaka, Aya and Quynh, Anh Duong and Nishijima, Akira and Miyamoto, Yuichiro and Mori, Mayuyo and Hiraike, Osamu and Hasegawa, Kosei and Ushiku, Tetsuo and Oda, Katsutoshi and Hirota, Yasushi and Osuga, Yutaka},
title = {BRCA1 Promoter Methylation in Ovarian Cancer: Clinical Relevance and a Novel Diagnostic Approach Using Fragment Analysis},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70078}
}
EUVIMED